A cancer vaccine finally clears its biggest hurdle
On August 19, Moderna announced that people who'd had surgery for severe melanoma survived longer without their cancer coming back when they got a personalized mRNA vaccine alongside the immunotherapy drug pembrolizumab, compared with the immunotherapy alone 78675.
It's the first time a personalized cancer vaccine has posted positive results in a final-stage trial. Here's how it works: doctors sequence a patient's tumor, compare it to their healthy cells, and pick up to 34 mutated proteins unique to that cancer. The vaccine teaches the immune system to recognize exactly those proteins, using the same mRNA platform that made the Covid vaccine 78. Trials are already underway for lung, kidney, and bladder cancers. Moderna's CEO Stéphane Bancel called it "a pivotal moment"; Dr. Lennard Lee at Oxford called it a "landmark moment for cancer vaccines" 675.
What each field noticed (2)

Will personalised mRNA vaccines transform cancer treatments?
New Scientist stayed with the mechanics: why mRNA beats older vaccine technology on speed and cost, and how blocking the PD-1 "don't attack me" signal on cancer cells lets the immune system finish the job 78.
Read the storyWhat went right this week
Positive News stayed with what it means for patients right now, quoting the oncologists calling it a genuine turning point rather than an incremental step, even while the full trial data hasn't been published yet 675.
Read the story